Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Mouse (Murine) PLAUR Anticorps:
anti-Human PLAUR Anticorps:
anti-Rat (Rattus) PLAUR Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Mouse (Murine) Polyclonal PLAUR Primary Antibody pour BR, CyTOF - ABIN5013025
Zhang, Cai, López-Guisa, Collins, Eddy: Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein. dans Journal of the American Society of Nephrology : JASN 2004
Show all 7 Pubmed References
Human Polyclonal PLAUR Primary Antibody pour WB - ABIN1944762
Roldan, Cubellis, Masucci, Behrendt, Lund, Danø, Appella, Blasi: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. dans The EMBO journal 1990
Show all 5 Pubmed References
Human Polyclonal PLAUR Primary Antibody pour IHC (p), WB - ABIN966859
Wang, Yang, Jamaluddin, Boyd: The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. dans The Journal of biological chemistry 2004
Show all 2 Pubmed References
Mouse (Murine) Polyclonal PLAUR Primary Antibody pour FACS, WB - ABIN4900558
van Zoelen, Florquin, de Beer, Pater, Verstege, Meijers, van der Poll: Urokinase plasminogen activator receptor-deficient mice demonstrate reduced hyperoxia-induced lung injury. dans The American journal of pathology 2009
Show all 2 Pubmed References
Human Monoclonal PLAUR Primary Antibody pour FACS - ABIN2472715
Gadd, Majdic, Kasinrerk, Stockinger, Maurer, Eher, Knapp: M5, a phosphoinositol-linked human myelomonocytic activation-associated antigen. dans Clinical and experimental immunology 1990
Show all 3 Pubmed References
Human Monoclonal PLAUR Primary Antibody pour IHC (fro), FACS - ABIN2472714
Sillaber, Baghestanian, Hofbauer, Virgolini, Bankl, Füreder, Agis, Willheim, Leimer, Scheiner, Binder, Kiener, Bevec, Fritsch, Majdic, Kress, Gadner, Lechner, Valent: Molecular and functional characterization of the urokinase receptor on human mast cells. dans The Journal of biological chemistry 1997
Show all 3 Pubmed References
Human Monoclonal PLAUR Primary Antibody pour FACS - ABIN2472717
Mondino, Blasi: uPA and uPAR in fibrinolysis, immunity and pathology. dans Trends in immunology 2004
Show all 3 Pubmed References
The ratio of full-length versus cleaved uPAR as analysed by Western blotting and its regulation was assessed by addition of different protease inhibitors and transforming growth factor - beta1 (TGF-beta1 (Montrer TGFB1 Anticorps)). The role of uPAR cleavage in cell proliferation and migration was analysed using real-time cell analysis and invasion was assessed using the myoma invasion model
Plg-RKT (Montrer PLGRKT Anticorps) is required for plasminogen (Montrer PLG Anticorps) binding and macrophage migration in vivo
The synergy of circulating factor suPAR and APOL1 (Montrer APOL1 Anticorps) G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD.
Results identify soluble uPAR as a functional connection between the bone marrow and the kidney, and they implicate bone marrow immature myeloid cells as a key source of soluble uPAR that leads to glomerular dysfunction.
Plaur deficiency does not increase susceptibility to epileptogenesis after traumatic brain injury in an animal model.
Significance of the urokinase-type plasminogen activator (Montrer PLAU Anticorps) and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Findings indicate a significant correlation of uPAR cleavage with breast cancer progression, but the precise biological consequence(s) of the cleavage or the cleavage products still remains to be elucidated.
interaction of full-length suPAR with alphavbeta3 integrin expressed on podocytes results in down-modulation of nephrin (Montrer NPHS1 Anticorps) that may affect kidney functionality in different human pathologies characterized by increased concentration of suPAR.
In an in vivo murine angiogenesis model uPAR-deficient PTEN heterozygous animals increased the impaired angiogenic phenotype of uPAR knockout mice and were able to reverse the high invasive potential of PTEN heterozygotes.
uPAR contributes to macrophage driven atherosclerotic lesion formation.
uPAR and TF could potentially be attractive targets for molecular imaging and therapy in oral squamous cell carcinoma due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival.
These findings may show that presenting a high level of suPAR in migraine patients with attack and aura results to predisposition to occurring on the symptoms and that high levels of suPAR, procalcitonin and fibrinogen in patients with migraine result in neurogenic inflammation during migraine headaches.
IFN-gamma (Montrer IFNG Anticorps), CXCL16 (Montrer CXCL16 Anticorps) and uPAR are promising as effective biomarkers of disease activity, renal damage, and the activity of pathological lesions in systemic lupus erythematosus.
Main associations between PLAUR (urokinase plasminogen activator receptor) single nucleotide polymorphisms (SNPs) and markers of airway remodelling, and immunohistochemical analyses
Increased uPAR expression was detected in the derma of psoriatic lesions and in the stroma surrounding tumor cells in basal cell carcinomas.
study provides strong support in the role of L. reuteri in suppression of GC cell invasion by downregulation of pathways which is involved in extracellular matrix degradation such as uPA (Montrer PRAP1 Anticorps) and uPAR
Plasma plasminogen activator urokinase receptor (P-suPAR) concentrations are elevated in acute alcohol pancreatitis (AAP (Montrer APEH Anticorps)) and correlate with the severity of the disease, suggesting P-suPAR may serve as a prognostic marker for AAP (Montrer APEH Anticorps) severity on admission.
We show that the tumor-suppressive actions of MEPs are mediated by PAI-1 (Montrer SERPINE1 Anticorps), uPA (Montrer PRAP1 Anticorps) and its receptor, uPAR, and are sustained even in the presence of the CAFs (Montrer TBX1 Anticorps), which themselves enhance DCIS tumorigenesis via IL-6 (Montrer IL6 Anticorps) signaling.
We report on the impact of bispecific targeting on the toxicity risks associated with targeting of EGFR (Montrer EGFR Anticorps) and uPAR . Our results show that eBAT is safe and potentially effective at biologically active doses despite EGFR (Montrer EGFR Anticorps) targeting, supporting further translation for patients with sarcomas and other EGFR (Montrer EGFR Anticorps)-expressing malignancies.
Improved positron emission tomography imaging of glioblastoma cancer using novel (68)Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR).
Data show that urokinase-type plasminogen activator (uPA (Montrer PLAU Anticorps)) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA (Montrer PLAU Anticorps) receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1 (Montrer SERPINE1 Anticorps)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA (Montrer PLAU Anticorps)/uPAR binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
Data indicate that superoxide dismutase (SOD) inhibited high glucose (HG)-induced expression of uPAR and VEGF in bovine retinal microvascular endothelial cell (REC).
These data indicated that E. coli LPS (Montrer IRF6 Anticorps) led to an increase in u-PA (Montrer PLAU Anticorps) activity and RNA expression of u-PA (Montrer PLAU Anticorps) and u-PAR in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
the interaction between uPAR and Man-6-P/IGF2R (Montrer IGF2R Anticorps) is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/IGF2R (Montrer IGF2R Anticorps) by different mechanisms.
This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.
urokinase plasminogen activator surface receptor
, plasminogen activator, urokinase receptor
, urokinase plasminogen activator receptor
, urokinase-type plasminogen activator receptor
, monocyte activation antigen Mo3
, u-plasminogen activator receptor form 2
, urokinase-type plasminogen activator (uPA) receptor
, plasminogen activator urokinase receptor 3
, urinary plasminogen activator receptor 2
, urinary plasminogen activator receptor 3